BMS Anti-Myostatin Adnectin Program (March 2016)

On March 30, 2016, PPMD and Bristol-Myers Squibb (BMS) hosted a webinar to discuss the BMS Anti-Myostatin Adnectin Program, recent preliminary data from the first-in-human study of the BMS anti-myostatin, and a clinical trial that BMS is conducting to test this drug in boys with Duchenne muscular dystrophy. Visit BMS Study Connect Patient and Care Giver Portal to subscribe for updates on the Duchenne clinical study(s) at http://bmsstudyconnect.com or visit http://clinicaltrials.gov. For any additional questions please call or email BMS at 855-907-3286 / clinical.trials@bms.com.